15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Autolus Therapeutics Ltd, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $10.00 to $10.00, so the covering firms are broadly aligned. The average target of $10.00 sits 376% above the current $2.10. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 3 over recent months. On the fundamentals, the Street sees revenue growth near 72% this year and 48% next, consensus EPS building from about $-0.17 next quarter toward $-0.63 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Autolus Therapeutics Ltd.
As of Sep, 3 of 3 firms rate AUTL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
AUTL EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.20 – $-0.13 · 6 analysts · -50% YoY
Next period, 6 analysts expect Autolus Therapeutics Ltd to earn $-0.17 a share (range $-0.20 – $-0.13), versus $-0.34 a year earlier. Full-year consensus is $-0.79, growing to $-0.63 the year after.
REVENUE · NEXT QUARTER
$38.4M
Range $32.0M – $43.5M · 6 analysts · +45% YoY
Revenue is expected to reach $38.4M (range $32.0M – $43.5M), +45.0% year-over-year. Full-year consensus is $149.8M, rising to $192.4M next year.
Top analysts covering Autolus Therapeutics Ltd
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AUTL.
#1
Gil Blum
Needham · Rank #340
Buy
$10.00+376.2% to target
Overall win rate
26%
+ Follow
#2
Emily Bodnar
HC Wainwright & Co. · Rank #399
Buy
$10.00+376.2% to target
Overall win rate
23%
+ Follow
#3
Salim Syed
Mizuho
Buy
$10.00+376.2% to target
Coverage
—
+ Follow
#4
RS
Rajan Sharma
Goldman Sachs
Buy
$5.80+176.2% to target
Coverage
—
+ Follow
#5
Asthika Goonewardene
Truist Securities
Buy
$8.00+281.0% to target
Coverage
—
+ Follow
AUTL stock forecast FAQ
What is AUTL's average 12-month price target?+
The 2 analysts with a live target average $10.00 for Autolus Therapeutics Ltd over the next 12 months, ranging from a $10.00 high to a $10.00 low.
Is AUTL stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover AUTL?+
3 analysts have an active rating on Autolus Therapeutics Ltd, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering AUTL?+
Among analysts who currently cover AUTL, Gil Blum of Needham has the strongest overall Quantellect track record (Rank #340). Their current call is Buy with a $10.00 target.
What is Autolus Therapeutics Ltd's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.20 – $-0.13) across 6 analysts. Full-year EPS is projected at $-0.79, rising to $-0.63 the following year.
How much revenue is Autolus Therapeutics Ltd expected to report next quarter?+
Consensus revenue is $38.4M (range $32.0M – $43.5M). Full-year revenue is projected at $149.8M, growing to $192.4M next year.
Have analysts been upgrading or downgrading AUTL lately?+
As of Sep, 3 of 3 firms rate AUTL a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AUTL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
